schliessen

Filtern

 

Bibliotheken

Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER

ABSTRACT—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminu... Full description

Journal Title: Hypertension 2003, Vol.41 (5), p.1063-1071
Main Author: Mogensen, Carl Erik
Other Authors: Viberti, Giancarlo , Halimi, Serge , Ritz, Eberhard , Ruilope, Luis , Jermendy, Gyorgy , Widimsky, Jiri , Sareli, Pinchas , Taton, Jan , Rull, Juan , Erdogan, Gurbuz , De Leeuw, Pieter W , Ribeiro, Arthur , Sanchez, Ramiro , Mechmeche, Rachid , Nolan, John , Sirotiakova, Jana , Hamani, Ahmed , Scheen, Andre , Hess, Bernhard , Luger, Anton , Thomas, Stephen M
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Philadelphia, PA: Am Heart Assoc
ID: ISSN: 0194-911X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_2077
title: Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
format: Article
creator:
  • Mogensen, Carl Erik
  • Viberti, Giancarlo
  • Halimi, Serge
  • Ritz, Eberhard
  • Ruilope, Luis
  • Jermendy, Gyorgy
  • Widimsky, Jiri
  • Sareli, Pinchas
  • Taton, Jan
  • Rull, Juan
  • Erdogan, Gurbuz
  • De Leeuw, Pieter W
  • Ribeiro, Arthur
  • Sanchez, Ramiro
  • Mechmeche, Rachid
  • Nolan, John
  • Sirotiakova, Jana
  • Hamani, Ahmed
  • Scheen, Andre
  • Hess, Bernhard
  • Luger, Anton
  • Thomas, Stephen M
subjects:
  • Adult
  • Aged
  • albuminuria
  • Albuminuria - drug therapy
  • Albuminuria - etiology
  • Albuminuria - urine
  • Albuminuria/drug therapy/etiology/urine
  • angiotensin-converting enzyme
  • Antihypertensive agents
  • Antihypertensive Agents - adverse effects
  • Antihypertensive Agents - therapeutic use
  • Antihypertensive Agents/adverse effects/therapeutic use
  • Biological and medical sciences
  • Blood Pressure - drug effects
  • Cardiovascular & respiratory systems
  • Cardiovascular system
  • Cough - chemically induced
  • diabetes mellitus
  • Diabetes Mellitus, Type 2 - complications
  • Diabetes Mellitus, Type 2 - physiopathology
  • Diabetes Mellitus, Type 2/complications/physiopathology
  • Dizziness - chemically induced
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Therapy, Combination
  • Enalapril - adverse effects
  • Enalapril - therapeutic use
  • Enalapril/adverse effects/therapeutic use
  • Female
  • Follow-Up Studies
  • Human health sciences
  • Humans
  • hypertension, renal
  • Indapamide - adverse effects
  • Indapamide - therapeutic use
  • Indapamide/adverse effects/therapeutic use
  • Male
  • Medical sciences
  • microalbuminuria
  • Middle Aged
  • Perindopril - adverse effects
  • Perindopril - therapeutic use
  • Perindopril/adverse effects/therapeutic use
  • Pharmacie, pharmacologie & toxicologie
  • Pharmacology. Drug treatments
  • Pharmacy, pharmacology & toxicology
  • Sciences de la santé humaine
  • Systèmes cardiovasculaire & respiratoire
  • Treatment Outcome
ispartof: Hypertension, 2003, Vol.41 (5), p.1063-1071
description: ABSTRACT—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP ≥140 mm Hg,
language: eng
source:
identifier: ISSN: 0194-911X
fulltext: no_fulltext
issn:
  • 0194-911X
  • 1524-4563
  • 1524-4563
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4155574
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_liege
recordidTN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_2077
sourceformatXML
sourcesystemPC
sourcerecordid335062661
originalsourceidFETCH-LOGICAL-15493-a9640f078cd1d8a94c5ce0589e2e4ebffa66b74a45c465482a7ad042b02d02660
addsrcrecordideNqNUV1v0zAUjRCIlcFfQNEkHtPZzrWT7IlpK6xSEVUFEjxZN8lN45HGnZ2s7N_jrpWKeMKSdf1xzvXxOVF0wdmUc8UvGZ_e_VxO2X4oKCCdSp5n-VTmL6IJlwISkCp9GU0YLyApOP9xFr3x_p4xDgDZ6-iMCyUhY2oSPcyahqohtk28sLvk1nqKl-RMX9utM93lvK9xixtTU2z7-Lorx43pR2cwNn18a7CkgfxVvHShOvy9P_0btKK1I--N7QNmNfsyn63eRq8a7Dy9O9bz6Pun2bebu2Tx9fP85nqRcAlFmmChgDUsy6ua1zkWUMmKmMwLEgRUNg0qVWaAICsIn8kFZlgzECUTNRNKsfOIH_p2htakrSuNfhTaojmsx26tsdIlaSFUrgXLssC5OHC2zj6M5Ad9b0fXB5nhXoqcAS8C6OoAqpz13lGjg1MbdE-aM70PSDOuQ0D6FJB-DkjLPJDfH18Yyw3VJ-oxkQD4cASgr7BrHPaV8SccZHlowwPu4z8qKjPgEJweHJru_7TAocXOdiE9_6sbd-R0S9gN7TMDgjOJYCxlMuySMHl6MrY163ZnHGncBI4bdPu0JTdQv88bW9TAtQxCVMr-AGKEzWs
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid205280419
display
typearticle
titleEffect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
creatorMogensen, Carl Erik ; Viberti, Giancarlo ; Halimi, Serge ; Ritz, Eberhard ; Ruilope, Luis ; Jermendy, Gyorgy ; Widimsky, Jiri ; Sareli, Pinchas ; Taton, Jan ; Rull, Juan ; Erdogan, Gurbuz ; De Leeuw, Pieter W ; Ribeiro, Arthur ; Sanchez, Ramiro ; Mechmeche, Rachid ; Nolan, John ; Sirotiakova, Jana ; Hamani, Ahmed ; Scheen, Andre ; Hess, Bernhard ; Luger, Anton ; Thomas, Stephen M
creatorcontribMogensen, Carl Erik ; Viberti, Giancarlo ; Halimi, Serge ; Ritz, Eberhard ; Ruilope, Luis ; Jermendy, Gyorgy ; Widimsky, Jiri ; Sareli, Pinchas ; Taton, Jan ; Rull, Juan ; Erdogan, Gurbuz ; De Leeuw, Pieter W ; Ribeiro, Arthur ; Sanchez, Ramiro ; Mechmeche, Rachid ; Nolan, John ; Sirotiakova, Jana ; Hamani, Ahmed ; Scheen, Andre ; Hess, Bernhard ; Luger, Anton ; Thomas, Stephen M ; Preterax in Albuminuria Regression (PREMIER) Study Group
descriptionABSTRACT—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP ≥140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59±9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 μg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (−3.0 [95% CI −5.6, −0.4], P =0.012; systolic BP −1.5 [95% CI −3.0, −0.1] diastolic BP P =0.019) and AER −42% (95% CI −50%, −33%) versus −27% (95% CI −37%, −16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection.
identifier
0ISSN: 0194-911X
1ISSN: 1524-4563
2EISSN: 1524-4563
3DOI: 10.1161/01.HYP.0000064943.51878.58
4PMID: 12654706
5CODEN: HPRTDN
languageeng
publisherPhiladelphia, PA: Am Heart Assoc
subjectAdult ; Aged ; albuminuria ; Albuminuria - drug therapy ; Albuminuria - etiology ; Albuminuria - urine ; Albuminuria/drug therapy/etiology/urine ; angiotensin-converting enzyme ; Antihypertensive agents ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Antihypertensive Agents/adverse effects/therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular & respiratory systems ; Cardiovascular system ; Cough - chemically induced ; diabetes mellitus ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes Mellitus, Type 2/complications/physiopathology ; Dizziness - chemically induced ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Therapy, Combination ; Enalapril - adverse effects ; Enalapril - therapeutic use ; Enalapril/adverse effects/therapeutic use ; Female ; Follow-Up Studies ; Human health sciences ; Humans ; hypertension, renal ; Indapamide - adverse effects ; Indapamide - therapeutic use ; Indapamide/adverse effects/therapeutic use ; Male ; Medical sciences ; microalbuminuria ; Middle Aged ; Perindopril - adverse effects ; Perindopril - therapeutic use ; Perindopril/adverse effects/therapeutic use ; Pharmacie, pharmacologie & toxicologie ; Pharmacology. Drug treatments ; Pharmacy, pharmacology & toxicology ; Sciences de la santé humaine ; Systèmes cardiovasculaire & respiratoire ; Treatment Outcome
ispartofHypertension, 2003, Vol.41 (5), p.1063-1071
rights
02003 American Heart Association, Inc.
12003 INIST-CNRS
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-15493-a9640f078cd1d8a94c5ce0589e2e4ebffa66b74a45c465482a7ad042b02d02660
citesFETCH-LOGICAL-15493-a9640f078cd1d8a94c5ce0589e2e4ebffa66b74a45c465482a7ad042b02d02660
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14785801$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12654706$$D View this record in MEDLINE/PubMed
2$$Uhttp://hyper.ahajournals.org/cgi/content/full/41/5/1063$$DView Additional URL From ORBi
search
creatorcontrib
0Mogensen, Carl Erik
1Viberti, Giancarlo
2Halimi, Serge
3Ritz, Eberhard
4Ruilope, Luis
5Jermendy, Gyorgy
6Widimsky, Jiri
7Sareli, Pinchas
8Taton, Jan
9Rull, Juan
10Erdogan, Gurbuz
11De Leeuw, Pieter W
12Ribeiro, Arthur
13Sanchez, Ramiro
14Mechmeche, Rachid
15Nolan, John
16Sirotiakova, Jana
17Hamani, Ahmed
18Scheen, Andre
19Hess, Bernhard
20Luger, Anton
21Thomas, Stephen M
22Preterax in Albuminuria Regression (PREMIER) Study Group
title
0Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
1Hypertension
addtitleHypertension
descriptionABSTRACT—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP ≥140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59±9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 μg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (−3.0 [95% CI −5.6, −0.4], P =0.012; systolic BP −1.5 [95% CI −3.0, −0.1] diastolic BP P =0.019) and AER −42% (95% CI −50%, −33%) versus −27% (95% CI −37%, −16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection.
subject
0Adult
1Aged
2albuminuria
3Albuminuria - drug therapy
4Albuminuria - etiology
5Albuminuria - urine
6Albuminuria/drug therapy/etiology/urine
7angiotensin-converting enzyme
8Antihypertensive agents
9Antihypertensive Agents - adverse effects
10Antihypertensive Agents - therapeutic use
11Antihypertensive Agents/adverse effects/therapeutic use
12Biological and medical sciences
13Blood Pressure - drug effects
14Cardiovascular & respiratory systems
15Cardiovascular system
16Cough - chemically induced
17diabetes mellitus
18Diabetes Mellitus, Type 2 - complications
19Diabetes Mellitus, Type 2 - physiopathology
20Diabetes Mellitus, Type 2/complications/physiopathology
21Dizziness - chemically induced
22Dose-Response Relationship, Drug
23Double-Blind Method
24Drug Therapy, Combination
25Enalapril - adverse effects
26Enalapril - therapeutic use
27Enalapril/adverse effects/therapeutic use
28Female
29Follow-Up Studies
30Human health sciences
31Humans
32hypertension, renal
33Indapamide - adverse effects
34Indapamide - therapeutic use
35Indapamide/adverse effects/therapeutic use
36Male
37Medical sciences
38microalbuminuria
39Middle Aged
40Perindopril - adverse effects
41Perindopril - therapeutic use
42Perindopril/adverse effects/therapeutic use
43Pharmacie, pharmacologie & toxicologie
44Pharmacology. Drug treatments
45Pharmacy, pharmacology & toxicology
46Sciences de la santé humaine
47Systèmes cardiovasculaire & respiratoire
48Treatment Outcome
issn
00194-911X
11524-4563
21524-4563
fulltextfalse
rsrctypearticle
creationdate2003
recordtypearticle
recordideNqNUV1v0zAUjRCIlcFfQNEkHtPZzrWT7IlpK6xSEVUFEjxZN8lN45HGnZ2s7N_jrpWKeMKSdf1xzvXxOVF0wdmUc8UvGZ_e_VxO2X4oKCCdSp5n-VTmL6IJlwISkCp9GU0YLyApOP9xFr3x_p4xDgDZ6-iMCyUhY2oSPcyahqohtk28sLvk1nqKl-RMX9utM93lvK9xixtTU2z7-Lorx43pR2cwNn18a7CkgfxVvHShOvy9P_0btKK1I--N7QNmNfsyn63eRq8a7Dy9O9bz6Pun2bebu2Tx9fP85nqRcAlFmmChgDUsy6ua1zkWUMmKmMwLEgRUNg0qVWaAICsIn8kFZlgzECUTNRNKsfOIH_p2htakrSuNfhTaojmsx26tsdIlaSFUrgXLssC5OHC2zj6M5Ad9b0fXB5nhXoqcAS8C6OoAqpz13lGjg1MbdE-aM70PSDOuQ0D6FJB-DkjLPJDfH18Yyw3VJ-oxkQD4cASgr7BrHPaV8SccZHlowwPu4z8qKjPgEJweHJru_7TAocXOdiE9_6sbd-R0S9gN7TMDgjOJYCxlMuySMHl6MrY163ZnHGncBI4bdPu0JTdQv88bW9TAtQxCVMr-AGKEzWs
startdate20030501
enddate20030501
creator
0Mogensen, Carl Erik
1Viberti, Giancarlo
2Halimi, Serge
3Ritz, Eberhard
4Ruilope, Luis
5Jermendy, Gyorgy
6Widimsky, Jiri
7Sareli, Pinchas
8Taton, Jan
9Rull, Juan
10Erdogan, Gurbuz
11De Leeuw, Pieter W
12Ribeiro, Arthur
13Sanchez, Ramiro
14Mechmeche, Rachid
15Nolan, John
16Sirotiakova, Jana
17Hamani, Ahmed
18Scheen, Andre
19Hess, Bernhard
20Luger, Anton
21Thomas, Stephen M
general
0Am Heart Assoc
1American Heart Association, Inc
2Lippincott
3American Heart Association
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9K9.
10Q33
sort
creationdate20030501
titleEffect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
authorMogensen, Carl Erik ; Viberti, Giancarlo ; Halimi, Serge ; Ritz, Eberhard ; Ruilope, Luis ; Jermendy, Gyorgy ; Widimsky, Jiri ; Sareli, Pinchas ; Taton, Jan ; Rull, Juan ; Erdogan, Gurbuz ; De Leeuw, Pieter W ; Ribeiro, Arthur ; Sanchez, Ramiro ; Mechmeche, Rachid ; Nolan, John ; Sirotiakova, Jana ; Hamani, Ahmed ; Scheen, Andre ; Hess, Bernhard ; Luger, Anton ; Thomas, Stephen M
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-15493-a9640f078cd1d8a94c5ce0589e2e4ebffa66b74a45c465482a7ad042b02d02660
rsrctypearticles
prefilterarticles
languageeng
creationdate2003
topic
0Adult
1Aged
2albuminuria
3Albuminuria - drug therapy
4Albuminuria - etiology
5Albuminuria - urine
6Albuminuria/drug therapy/etiology/urine
7angiotensin-converting enzyme
8Antihypertensive agents
9Antihypertensive Agents - adverse effects
10Antihypertensive Agents - therapeutic use
11Antihypertensive Agents/adverse effects/therapeutic use
12Biological and medical sciences
13Blood Pressure - drug effects
14Cardiovascular & respiratory systems
15Cardiovascular system
16Cough - chemically induced
17diabetes mellitus
18Diabetes Mellitus, Type 2 - complications
19Diabetes Mellitus, Type 2 - physiopathology
20Diabetes Mellitus, Type 2/complications/physiopathology
21Dizziness - chemically induced
22Dose-Response Relationship, Drug
23Double-Blind Method
24Drug Therapy, Combination
25Enalapril - adverse effects
26Enalapril - therapeutic use
27Enalapril/adverse effects/therapeutic use
28Female
29Follow-Up Studies
30Human health sciences
31Humans
32hypertension, renal
33Indapamide - adverse effects
34Indapamide - therapeutic use
35Indapamide/adverse effects/therapeutic use
36Male
37Medical sciences
38microalbuminuria
39Middle Aged
40Perindopril - adverse effects
41Perindopril - therapeutic use
42Perindopril/adverse effects/therapeutic use
43Pharmacie, pharmacologie & toxicologie
44Pharmacology. Drug treatments
45Pharmacy, pharmacology & toxicology
46Sciences de la santé humaine
47Systèmes cardiovasculaire & respiratoire
48Treatment Outcome
toplevelpeer_reviewed
creatorcontrib
0Mogensen, Carl Erik
1Viberti, Giancarlo
2Halimi, Serge
3Ritz, Eberhard
4Ruilope, Luis
5Jermendy, Gyorgy
6Widimsky, Jiri
7Sareli, Pinchas
8Taton, Jan
9Rull, Juan
10Erdogan, Gurbuz
11De Leeuw, Pieter W
12Ribeiro, Arthur
13Sanchez, Ramiro
14Mechmeche, Rachid
15Nolan, John
16Sirotiakova, Jana
17Hamani, Ahmed
18Scheen, Andre
19Hess, Bernhard
20Luger, Anton
21Thomas, Stephen M
22Preterax in Albuminuria Regression (PREMIER) Study Group
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8ProQuest Health & Medical Complete (Alumni)
9Université de Liège - Open Repository and Bibliography (ORBI)
jtitleHypertension
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Mogensen, Carl Erik
1Viberti, Giancarlo
2Halimi, Serge
3Ritz, Eberhard
4Ruilope, Luis
5Jermendy, Gyorgy
6Widimsky, Jiri
7Sareli, Pinchas
8Taton, Jan
9Rull, Juan
10Erdogan, Gurbuz
11De Leeuw, Pieter W
12Ribeiro, Arthur
13Sanchez, Ramiro
14Mechmeche, Rachid
15Nolan, John
16Sirotiakova, Jana
17Hamani, Ahmed
18Scheen, Andre
19Hess, Bernhard
20Luger, Anton
21Thomas, Stephen M
aucorpPreterax in Albuminuria Regression (PREMIER) Study Group
formatjournal
genrearticle
ristypeJOUR
atitleEffect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
jtitleHypertension
addtitleHypertension
date2003-05-01
risdate2003
volume41
issue5
spage1063
epage1071
pages1063-1071
issn
00194-911X
11524-4563
eissn1524-4563
codenHPRTDN
notes
0scopus-id:0038185261
1http://hyper.ahajournals.org/cgi/content/full/41/5/1063
abstractABSTRACT—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP ≥140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59±9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 μg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (−3.0 [95% CI −5.6, −0.4], P =0.012; systolic BP −1.5 [95% CI −3.0, −0.1] diastolic BP P =0.019) and AER −42% (95% CI −50%, −33%) versus −27% (95% CI −37%, −16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection.
cop
0Philadelphia, PA
1Hagerstown, MD
pubAm Heart Assoc
pmid12654706
doi10.1161/01.HYP.0000064943.51878.58
oafree_for_read